Back to top
more

Hologic (HOLX)

(Real Time Quote from BATS)

$79.39 USD

79.39
437,021

+0.10 (0.13%)

Updated Nov 8, 2024 02:51 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

QIAGEN Partners With Tecan to Advance QFT-Plus Diagnostic Test

by Zacks Equity Research

QIAGEN (QGEN) believes that the partnership will aid in improvising the automation of pre-analytic manual steps, leading to its QuantiFERON-TB Gold Plus test.

Here's Why You Should Add Amedisys (AMED) to Your Portfolio

by Zacks Equity Research

Amedisys (AMED) is currently focusing on improving clinical quality.

Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio

by Zacks Equity Research

Bio-Rad (BIO) seeing solid revenue growth in geographies like Americas and Asia Pacific buoys optimism.

HOLX vs DXCM: Which MedTech Stock is a Better Investment Pick?

by Zacks Equity Research

DexCom (DXCM) looks stronger than Hologic (HOLX) when it comes to current-year earnings and revenue projections as well as fundamentals.

Here's Why You Must Add Hologic (HOLX) to Your Portfolio Now

by Zacks Equity Research

Hologic's (HOLX) management is impressed with continued growth in the core Molecular Diagnostics sub-segment.

Hologic (HOLX) Receives Global Nods for Omni Hysteroscope

by Zacks Equity Research

Hologic's (HOLX) receipt of approvals for Omni Hysteroscope in Canada and Europe is expected to boost the GYN Surgical arm.

Here's Why Momentum Investors Will Love Hologic (HOLX)

by Zacks Equity Research

Does Hologic (HOLX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Hologic's (HOLX) Q1 Earnings Beat Estimates, Guidance Raised

by Zacks Equity Research

Hologic (HOLX) gains from solid double-digit constant currency growth in core businesses like U.S. Breast Health, International and Global Molecular Diagnostics.

Hologic (HOLX) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Hologic (HOLX) delivered earnings and revenue surprises of 1.75% and 1.51%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

What's Setting the Tone for Hologic's (HOLX) Q1 Earnings?

by Zacks Equity Research

Strength in the Breast Health business, Panther system and international business is likely to boost Hologic's (HOLX) top line in Q1.

Hologic (HOLX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Hologic Stock Rides on Impressive Preliminary Q1 Result

by Zacks Equity Research

Hologic's (HOLX) strong top line is primarily expected on the back of balanced growth across a majority of the company's segments in Q1.

Hologic's (HOLX) New Offering to Revitalize Cynosure Division

by Zacks Equity Research

The latest launch along with certain new developments is expected to boost top-line contribution from Hologic's (HOLX) Cynosure division in the near term.

Hologic Unveils Omni Hysteroscope, Boosts GYN Surgical Arm

by Zacks Equity Research

Hologic (HOLX) highlights that a direct visualization of the uterine cavity in women with abnormal uterine bleeding will set a benchmark for the medical test.

Why Is Hologic (HOLX) Up 1.9% Since Last Earnings Report?

by Zacks Equity Research

Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Hologic (HOLX) Q4 Earnings Miss, Revenues Top Estimates

by Zacks Equity Research

Tough year-over-year comparisons and soft Diagnostics sales hurt Hologic's (HOLX) performance in Q4.

Hologic (HOLX) Misses Q4 Earnings Estimates

by Zacks Equity Research

Hologic (HOLX) delivered earnings and revenue surprises of -1.69% and 1.04%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

What's Setting the Tone for Hologic's (HOLX) Q4 Earnings?

by Zacks Equity Research

Strength in the Breast Health business, Panther system and increasing utilization of Aptima women's health assays will boost Hologic's (HOLX) top line in Q4.

Hologic (HOLX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Hologic (HOLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Women Health a Prime Concern Worldwide: 3 Stocks in Focus

by Zacks Equity Research

Women health care gradually gaining importance globally, investors might keep an eye on a few stocks.

    Hologic's Focal Therapeutics Buyout to Boost Breast Health Arm

    by Zacks Equity Research

    Hologic (HOLX) progresses with initiatives to boost the Breast Health unit. The recent buyout is likely to widen portfolio and fortify Hologic's position in the breast conserving surgery market.

      Hologic (HOLX) Down 4.8% Since Last Earnings Report: Can It Rebound?

      by Zacks Equity Research

      Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

        Hologic Launches Fluent Fluid Management System, Widens Suite

        by Zacks Equity Research

        Hologic (HOLX) adopts initiatives to boost the GYN Surgical segment.

          Hologic (HOLX) Beats Earnings and Revenue Estimates in Q3

          by Zacks Equity Research

          Solid growth at Hologic's (HOLX) Breast Health and international business drives top line in Q3.

            Medical Product Stock Earnings on Jul 31: HOLX, NUVA, QSII

            by Zacks Equity Research

            Let's take a look at the factors that are likely to influence the earnings results of a few MedTech bigwigs within the broader Medical universe.